نتایج جستجو برای: teriflunomide

تعداد نتایج: 247  

Journal: :Neurology 2016
Paul O'Connor Giancarlo Comi Mark S Freedman Aaron E Miller Ludwig Kappos Jean-Pierre Bouchard Christine Lebrun-Frenay Jan Mares Myriam Benamor Karthinathan Thangavelu Jinjun Liang Philippe Truffinet Victoria J Lawson Jerry S Wolinsky

OBJECTIVE To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). METHODS A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to te...

2015
AM Hopkins MD Wiese SM Proudman CE O'Doherty DJR Foster RN Upton

A semiphysiologically based pharmacokinetic (semi-PBPK) population model was used to evaluate the influence of enterohepatic recycling and protein binding, as well as the effect of genetic variability in CYP1A2, CYP2C19, and ABCG2, on the large interindividual variability of teriflunomide (active metabolite) concentrations following leflunomide administration in rheumatoid arthritis (RA) patien...

2015
Jacek Kujawski Marek K. Bernard Elżbieta Jodłowska Kornelia Czaja Beata Drabińska

Leflunomide is a disease-modifying antirheumatic drug with antiinflammatory and immunosuppressive activity used for the treatment of psoriatic and rheumatoid arthritis. It undergoes rapid metabolization to teriflunomide, a metabolite that is responsible for the biological activity of leflunomide. Continuing our investigations on the interactions of biologically important azahetarenes with the e...

2016
André Duquette Anne Julie Frenette Maxime Doré

OBJECTIVE To report the case of a patient treated with leflunomide that presented with chronic diarrhea associated with high teriflunomide blood concentration. An 84-year-old woman taking leflunomide 20 mg once daily for the past 2 years to treat rheumatoid arthritis (RA) was investigated for severe chronic diarrhea that had been worsening for the past 5 months. The patient's general condition ...

Journal: :The New England journal of medicine 2011
Paul O'Connor Jerry S Wolinsky Christian Confavreux Giancarlo Comi Ludwig Kappos Tomas P Olsson Hadj Benzerdjeb Philippe Truffinet Lin Wang Aaron Miller Mark S Freedman

BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS We concluded a randomized trial involving 1088 patients with multiple sclerosis, 18 to 55 years of age, with a score of 0 to 5.5 on the Expanded Disability Status Scale and at least one relapse in the previous year or at least two relapses in the previous 2 years. Patients were ...

Journal: :Neurology 2006
P W O'Connor D Li M S Freedman A Bar-Or G P A Rice C Confavreux D W Paty J A Stewart R Scheyer

BACKGROUND Teriflunomide, a dihydro-orotate dehydrogenase inhibitor, has immunomodulatory effects, including the ability to suppress experimental allergic encephalomyelitis. In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses. METHODS Patients (n = 179) with relapsing-r...

2013
Garth E. Ringheim Lan Lee Lynn Laws-Ricker Tomas Delohery Li Liu Donghui Zhang Nicholas Colletti Timothy J. Soos Kendra Schroeder Barbara Fanelli Nian Tian Christopher W. Arendt Deborah Iglesias-Bregna Margaret Petty Zhongqi Ji George Qian Rajula Gaur Daniel Weinstock Jean Cavallo Juventas Telsinskas Kathleen McMonagle-Strucko

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells,...

2015
Amit Bar-Or Heinz Wiendl Barry Miller Myriam Benamor Philippe Truffinet Meg Church Francoise Menguy-Vacheron

OBJECTIVE To evaluate immune responses to neoantigen and recall antigens in healthy subjects treated with teriflunomide. METHODS This was a randomized, double-blind, placebo-controlled study. Subjects received oral teriflunomide (70 mg once daily for 5 days followed by 14 mg once daily for 25 days) or placebo for 30 days. Antibody responses were evaluated following rabies vaccination (neoanti...

2016
Javier Ochoa-Repáraz Sara L. Colpitts Christopher Kircher Eli J. Kasper Kiel M. Telesford Sakhina Begum-Haque Anudeep Pant Lloyd H. Kasper

OBJECTIVE To determine whether as an orally delivered treatment, teriflunomide, an inhibitor of the mitochondrial enzyme dihydroorotate dehydrogenase approved to treat relapsing forms of multiple sclerosis, could affect gut-associated lymphoid tissue (GALT) immune responses functionally. METHODS C57BL/6 mice were treated orally with teriflunomide and flow cytometric analysis of immune GALT ce...

Journal: :Maedica 2013
Florina Antochi

T eriflunomide is an oral immunomo-du lator, an active metabolite of le-flunomide. Leflunomide is used in the long-term treatment of rheuma-toid arthritis and is metabolized to te riflunomide in vivo. The mechanism of action of teriflunomide is linked to reversibly inhibition of dihydroorotate dehydrogenase, a mithocondrial enzyme involved in de novo synthesis of pyrimidine for DNA replication....

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید